

Precision medicine is rapidly gaining prominence as a mainstream treatment approach in oncology. Coupled with the rise of precision medicine, oncology has also seen biomarker tests not just entering the mainstream but also shifting the way decisions are made. Join us as we explore the evolving landscape of precision medicine and biomarker testing and its impact on oncology markets across different tumor types and geographies.
Don't miss this opportunity to gain valuable knowledge and explore the frontiers of precision medicine in oncology. Secure your spot today!
Speakers:
Vladimir Bonevski
Associate Director, Global Oncology Product & Strategy - IQVIA
Lien Lybaert
CEO - Persomed
Kriti Jindal, M.S. (Pharm.)
Client Service Manager, Global Oncology - IQVIA